Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.68 |
| ▸ | TEK | Q02763 | 10/20 | 0.68 |
| ▸ | LCK | P06239 | 7/20 | 0.68 |
| ▸ | SRC | P12931 | 4/20 | 0.68 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.62 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.62 |
| ▸ | PRKDC | P78527 | 1/20 | 0.62 |
| ▸ | RET | P07949 | 5/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | FYN | P06241 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7007567 | 0.89 | KDR (0.71) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2074398 | 0.86 | PIK3CD (0.73) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL20162806 | 0.86 | KDR (0.58) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL30037235 | 0.86 | KDR (0.58) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2074335 | 0.84 | KDR (0.76) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL2074938 | 0.83 | KDR (0.64) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL13020096 | 0.82 | SRC (0.69) | KDRTEKLCKSRCFLT3 | |
| SCHEMBL20168253 | 0.81 | KDR (0.53) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL23170598 | 0.81 | KDR (0.67) | KDRTEKLCKSRCPIK3CD | |
| SCHEMBL7005359 | 0.81 | TEK (1.00) | KDRTEKLCKSRCPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331297-A1 | MODULATION OF PROTEIN TRAFFICKING | RAB1A, COPB1, GOLT1B | KDR 4598/4885TEK 4347/4885LCK 1980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.